Article
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Blood - 15 Nov 2005
Levine Ross L, Loriaux Marc, Huntly Brian J P, Loh Mignon L, Beran Miroslav, Stoffregen Eric, Berger Roland, Clark Jennifer J, Willis Stephanie G, Nguyen Kim T, Flores Nikki J, Estey Elihu, Gattermann Norbert, Armstrong Scott, Look A Thomas, Griffin James D, Bernard Olivier A, Heinrich Michael C, Gilliland D Gary, Druker Brian, Deininger Michael W N
Abstract excerpt
Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies. Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. We used direct sequence...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.